OncoSec: OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

(marketscreener.com) EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated , a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced a Type C meeting held with the US Food and Drug Administration on May...https://www.marketscreener.com/quote/stock/ONCOSEC-MEDICAL-INCORPORA-58740317/news/OncoSec-is-encouraged-after-FDA-meeting-to-discuss-proposed-neoadjuvant-melanoma-clinical-program-43865264/?utm_medium=RSS&utm_content=20230516